TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16940094
Drug: Clindamycin (CLI)
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin (CLI) 600 mg
Study: 16940094
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (MXF) 400 mg
Study: 15302567
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg per day (40 mg twice daily)
Study: 11753267
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's Wort (300 mg, three times a day for 14 days)
Study: 9266538
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 supplementation (90 mg/day)
Study: 8440431
Drug: Zaldaride maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaldaride maleate 20 mg
Study: 3758151
Drug: Topical beclomethasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclomethasone dipropionate suspension
Study: 31473111
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 g administered intravenously every 8 h for an average of 10.5 days
Study: 31473111
Drug: Meropenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 0.5 g administered intravenously every 8 h for an average of 10.5 days
Study: 23098170
Drug: Ingesting the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting the entire daily dose of ≥1 hypertension medication at bedtime
Study: 14532316
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 to 20 mg/wk)
Study: 10506633
Drug: Dexamethasone 0.75
Normalized name: dexamethasone 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.75 mg qid
Study: 10506633
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 800 mg orally every day
Study: 10506633
Drug: Fluoxymesterone 10
Normalized name: fluoxymesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone 10 mg orally bid
Study: 26509382
Drug: Low-dose CO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CO inhalation (1.2 mL·kg(‐1) body mass)
Study: 26509382
Drug: Low-dose CO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CO inhalation
Study: 22731245
Drug: Forskolin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forskolin and rutin (2 tablets per day)
Study: 22731245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal topical therapy only)
Study: 20668826
Drug: Hyperbaric levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric levobupivacaine 1.5 mg (perianal)
Study: 20668826
Drug: Hyperbaric levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric levobupivacaine 6 mg (saddle)
Study: 11878059
Drug: Xenical (orlistat)
Normalized name: orlistat Oral Capsule [Xenical]
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xenical (orlistat) 360 mg/day with diet
Study: 9536565
Drug: Sumatriptan 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 12.5 mg
Study: 23325368
Drug: Sumatriptan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (both doses)
Study: 7633301
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of apomorphine (0.005 mg/kg) in heroin addicts
Study: 7633301
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of apomorphine (0.005 mg/kg) in healthy volunteers
Study: 2673693
Drug: Miglitol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (300 mg/day)
Study: 363236
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (20 g)
Study: 363236
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid (in capsules)
Study: 12947434
Drug: Glycaemic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycaemic glucose equivalent (GGE) doses of 10 and 20 GGE for yams, biscuits, white rice, and porridge; 24 and 48 GGE for 2-minute noodles
Study: 9225069
Drug: Granulocyte colony‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) and erythropoietin (EPO)
Study: 1546144
Drug: Moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 200 mg b.i.d.
Study: 7954488
Drug: Brofaromine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine 75 mg b.i.d.
Study: 7954488
Drug: Mianserin 10
Normalized name: mianserin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 10 mg t.i.d.
Study: 7954488
Drug: Doxepin 25
Normalized name: doxepin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 25 mg t.i.d.
Study: 7954488
Drug: Brofaromine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (both doses)
Study: 7954488
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Moclobemide and Brofaromine)
Study: 2359974
Drug: Viscous bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous bolus (syrup; viscosity, 102 centipoise) at varying volumes (5, 10, 15, 20 ml)
Study: 2359974
Drug: Non-viscous bolus
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-viscous bolus (water; viscosity, 0.89 centipoise) at varying volumes (5, 10, 15, 20 ml)
Study: 12556685
Drug: 2% PRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% PRO 2000 Gel, once or twice daily for 14 days
Study: 12556685
Drug: 4% PRO
Normalized name: Stanimax 2.84% Pro Perio Mouthwash Dental Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% PRO 2000 Gel, twice daily for 14 days
Study: 8546555
Drug: Influenza and
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza and pneumococcal vaccines
Study: 2064515
Drug: Vitamin-K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K antagonists and dipyridamole
Study: 2064515
Drug: Vitamin-K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K antagonists and placebo
Study: 27245042
Drug: Jingui Shenqi
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jingui Shenqi pill combined with nifedipine sustained-release tablets
Study: 16715189
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg methylprednisolone (Group I)
Study: 3894216
Drug: Butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butoconazole nitrate cream (3-day course)
Study: 3894216
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate cream (7-day course)
Study: 21397284
Drug: Partially hydrogenated
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrogenated soybean oil (15 g/d TFA)
Study: 10719945
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (tranexamic acid with autologous blood collection, n = 32)
Study: 10719945
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (saline infusion, n = 43)
Study: 7504977
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of aprotinin
Study: 7504977
Drug: Classical doses
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical doses of aprotinin
Study: 3797115
Drug: Natural human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural human surfactant (60 mg surfactant/kg body weight)
Study: 27436880
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment arm
Study: 23551243
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D3 supplementation (2000 IU per day for 30 days)
Study: 23551243
Drug: Simulated summer
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated summer UV exposure (10 sunbed sessions to a total dose of 23.8 SED)
Study: 23551243
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (oral vitamin D3 and UV exposure)
Study: 23551243
Drug: Whole-body sunbed
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body sunbed exposure (4.8 SED twice weekly)
Study: 19501354
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg triptorelin (group A; n=172)
Study: 16681719
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8, sequence T‐‐>G
Study: 16681719
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2)
Study: 16681719
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m(2) and paclitaxel 150 mg/m(2)
Study: 16681719
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2) with sequence G‐‐>T
Study: 12809965
Drug: Statin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use (1892 patients, 21.9% of total); mean TC level of 5.99 mmol/L (231.6 mg/dL) at end of study; 1096 patients (57.9%) had TC levels above cutoff.
Study: 12809965
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin use (6761 patients, 78.1% of total); mean TC level of 6.24 mmol/L (241.4 mg/dL) at end of study; 5316 patients (78.6%) had TC levels above cutoff.
Study: 11182393
Drug: Subareolar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subareolar injection of technetium‐99 sulfur colloid and blue dye
Study: 11182393
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection of technetium‐99 sulfur colloid and blue dye
Study: 2496149
Drug: Fluvoxamine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine, 100 mg daily for 17 days
Study: 2496149
Drug: Clovoxamine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovoxamine, 150 mg daily for 17 days
Study: 323023
Drug: Tolamolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol (300 mg/day - 900 mg/day)
Study: 323023
Drug: Methyldopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (750 mg/day - 2250 mg/day)
Study: 26682608
Drug: 8-week gross
Normalized name: OSTERICUM GROSSESERRATUM ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week gross motor skills program (10 min. daily)
Study: 24135213
Drug: E‐couch program
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐couch program (unguided Web‐based program based on cognitive behavioral therapy and interpersonal therapy)
Study: 20605477
Drug: Mandibular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular nerve block (MNB) with 5 mL ropivacaine 0.5% for each block
Study: 18348597
Drug: memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine 20 mg/day
Study: 17146409
Drug: m-CPP 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP 0.5 mg/kg
Study: 7943920
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of triazolam p.o.
Study: 29988111
Drug: Catumaxomab followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catumaxomab followed by chemotherapy (FLOT)
Study: 25188566
Drug: Dynamic interpersonal
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic interpersonal group psychotherapy (DIGP), 16 sessions held weekly
Study: 10521742
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (20 mg)
Study: 8928194
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (topical nasal drop of 0.1% betamethasone for 12 patients and oral administration of prednisolone for 5 patients)
Study: 6388588
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose load with 50 g ethanol
Study: 6388588
Drug: Starch solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch solution (maize meal) and alcohol
Study: 25060690
Drug: Low-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ethanol intervention
Study: 22235808
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus 12 weekly music therapy sessions delivered by the Northern Ireland Music Therapy Trust
Study: 11895049
Drug: Lovastatin alone
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin alone administered with dinner
Study: 8544722
Drug: CFM (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFM (480 ml)
Study: 8544722
Drug: RM (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM (480 ml)
Study: 7002830
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Mianserin
Study: 7002830
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg Mianserin
Study: 7002830
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Mianserin
Study: 12145434
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + calcipotriol ointment (50 microg/g), applied twice daily
Study: 12145434
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + ointment vehicle
Study: 3143482
Drug: Ergotamine tartrate
Normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergotamine tartrate compound
Study: 29488226
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg Q2W
Study: 25594355
Drug: Gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel with active substances (hyaluronic acid, sericin, glycerol, urea)
Study: 16514482
Drug: IL-2 (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (5, 15, or 25 mcg/m2 on days 1, 8, and 15 starting in the second cycle)
Study: 16514482
Drug: IL-2 (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (35 mcg/m2, non-randomized)
Study: 6661620
Drug: Minocycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (200 mg)
Study: 6661620
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg)
Study: 22173570
Drug: Dexmedetomidine 0.1
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.1 μg/kg/min for 10 min loading dose, followed by 0.4 μg/kg/h continuous infusion
Study: 22173570
Drug: Propofol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.1 mg/kg/min for 10 min loading dose, followed by 1 mg/kg/h continuous infusion
Study: 19906800
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ca/d
Study: 19906800
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg Ca/d
Study: 12628633
Drug: no‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: no‐treatment control condition (n = 10)
Study: 7632029
Drug: diltiazem-trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem-trimetazidine (60 mg/24 h)
Study: 30074327
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg of clonidine with hyperbaric bupivacaine (BC15 group)
Study: 30074327
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg of clonidine with hyperbaric bupivacaine (BC30 group)
Study: 30074327
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg of clonidine with hyperbaric bupivacaine (BC60 group)
Study: 25682602
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg/kg/day for grade IIa manifestations
Study: 25682602
Drug: Prednisone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.5 mg/kg/day for grade IIa manifestations
Study: 25682602
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/kg/day for grade IIb or higher manifestations
Study: 25682602
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg/kg/day for grade IIb or higher manifestations
Study: 20454943
Drug: Standard-dose ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ganciclovir (5 mg/kg twice daily for 1 week)
Study: 20454943
Drug: Low-dose ganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ganciclovir (5 mg/kg twice daily for 1 week)
Study: 20454943
Drug: Standard-dose ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ganciclovir
Study: 20454943
Drug: Low-dose ganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ganciclovir
Study: 12019196
Drug: Rofecoxib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (125 mg, 100 micro Ci) in healthy subjects
Study: 12019196
Drug: Rofecoxib (142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (142 mg, 100 micro Ci) in cholecystectomy patients
Study: 7621843
Drug: Salbutamol CR
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol CR 8 mg b.i.d.
Study: 23154577
Drug: Postprandial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial exercise (walking on a motorized treadmill at ca. 50%V(·)o(2)max for 30 min) after glucose with OFTT cream intake
Study: 21632504
Drug: Id vaccine
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Id vaccine (Id-KLH + GM-CSF)
Study: 21632504
Drug: IgM-Id vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-Id vaccine
Study: 21632504
Drug: IgG-Id vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-Id vaccine
Study: 19098687
Drug: 25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/d of dehydroepiandrosterone
Study: 17101607
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g amino acids, 1.2 g glycerol, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Study: 17101607
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g amino acids, 1.5 g dextrose, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Study: 3602843
Drug: Ivermectin (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (100, 150, and 200 mcg/kg)
Study: 24598116
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution
Study: 20006290
Drug: Anma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma therapy (40-min session)
Study: 18200453
Drug: Probatory CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probatory CPAP therapy with follow-up examination
Study: 18200453
Drug: Immediate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prescription of CPAP device
Study: 18200453
Drug: Probatory CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probatory CPAP therapy
Study: 12575587
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy combined with anti-tumor drugs
Study: 3475036
Drug: Enoxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 600 mg, single dose
Study: 3475036
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg, single dose
Study: 3475036
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg every 12 h, four doses
Study: 3475036
Drug: All enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enoxacin doses
Study: 30597504
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral TXA 2 hours pre-operatively followed by 1-g oral TXA 3 hours post-operatively (group B)
Study: 30597504
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral TXA followed by 1-g oral TXA 3 and 7 hours post-operatively (group C)
Study: 30597504
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral TXA followed by 1-g oral TXA 3, 7 and 11 hours post-operatively (group D)
Study: 30597504
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral TXA followed by 1-g oral TXA 3, 7, 11 and 15 hours post-operatively (group E)
Study: 22565161
Drug: Once-daily MMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily MMX mesalamine 2.4 g/day